Mood and Psychosis Symptoms during the Menopause Transition (R01, R21 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts

This FOA uses the R01 grant mechanism, while the companion FOA (PAR-22-036 ) uses the R21 mechanism. Investigators proposing high risk/high reward projects, projects that lack preliminary data, or studies that utilize existing data may wish to apply using the R21 mechanism, while applicants with preliminary data who seek longer-term funding may wish to apply using the R01 mechanism.

Deadlines:

  • R01 Due Dates: Feb 5, Jun 5, Oct 5

  • R21 Due Dates: Feb 16, Jun 16, Oct 16

PAR-22-035 Expiration Date January 08, 2025

Agency Website

Areas of Interest

This FOA encourages applications from teams of diverse researchers. Teams may include but are not limited to members from the fields of neuroscience, engineering, endocrinology, epidemiology, reproductive medicine, gerontology, gynecology, pharmacology, psychiatry, and psychology with the expertise necessary to conduct rigorous research.

Funding Type

Grant

Eligibility

Faculty

Category

Engineering and Physical Sciences
Medical
Medical - Basic Science
Medical - Clinical Science
Social Sciences

External Deadline

June 5, 2022